- Nirvana Life Sciences Inc. (NIRV) reports progress with licensing and development of its Vancouver research and development facility
- The company believes psylocibin derived medicines can reduce the impacts of the opioids crisis
- The dealer’s license would permit research and development, manufacturing, import and export, sale to qualified investigators
- The dealer’s license is in the final review stage, completed by the end of this year
- It has also engaged Orion GMP Solutions to support the regulatory process with the design of a GMP compliant facility
- Nirvana Life Sciences Inc. (NIRV) is up 10.94 per cent trading at $0.71 per share as of 2:59 p.m. ET
Nirvana Life Sciences (NIRV) reports progress with licensing and development of its Vancouver research and development facility.
Nirvana Life Sciences believes psylocibin derived medicines can play a leading role in reducing the impacts of the opioids crisis and building healthier communities.
The company applied for a dealer’s license from Health Canada in July of last year. The application is currently in the final review stage, with approval expected by the end of this year.
The dealer’s license would permit research and development, manufacturing, import and export, sale to qualified investigators as well as sale to other licensed dealers in Canada for 29 different controlled substances. This includes novel compounds made of different tryptamines, phenethylamines, ergolines and aryl-cyclohexylamines.
To support this stage of this application, Nirvana Life Sciences has reached out to CannDelta Inc., a scientific and regulatory consulting company based in Toronto, to assist with the review being done by Health Canada’s Controlled Substance Division.
The company has also engaged Orion GMP Solutions to support the regulatory process with the design of a GMP compliant facility. Orion GMP is a leader in regulatory consulting for the controlled substances, cannabis, and pharmaceutical sectors.
The two firms have collaborated to develop a regulatory plan, design, and security plan for the proposed GMP compliant research and development facility, submitted along with the Dealer’s License application.
Bruce Clark, CEO of Nirvana commented,
“The projects that Nirvana has under way have the potential of making a meaningful difference for people and communities struggling because of addiction issues, the licensed facility will accelerate our research and development projects.”
Nirvana Life Sciences Inc. (NIRV) is up 10.94 per cent trading at $0.71 per share as of 2:59 p.m. ET.